STATEMENT OF NEED
Prostate cancer is the most common tumor type in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic castration-resistant prostate cancer is the primary cause of prostate-related mortality, accounting for an estimated 26,730 deaths annually. Median overall survival remains less than 2 years.
Urologists, oncologists, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC).
Upon completion of this activity, participants should be able to:
Oliver Sartor, MD (Chairperson)
C.E. and Bernadine Laborde Professor of Cancer Research
Tulane University School of Medicine
There is no fee to participate in or claim CME credit for this activity.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Cincinnati and i3 Health. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates: 1 ILNA point may be applied toward:
Diagnosis and Staging; Disease-Related Biology; Professional Practice; Scientific Basis for Practice; Symptom Management; Treatment .................1 point
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits. The University of Cincinnati will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The University of Cincinnati does not endorse any products or services.
Oliver Sartor, MD discloses that he has served as a consultant for AstraZeneca, Bayer, Bellicum, Bristol-Myers Squibb, Celgene, Dendreon, EMD Serono, Johnson & Johnson, Oncogenex, Pfizer, Sanofi-Aventis, and Tokai. He has received grants/research support from Bayer, Endocyte, Innocrin, Johnson & Johnson, and Sanofi-Aventis.
University of Cincinnati staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of Cincinnati, Office of Continuing Medical Education.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
UNAPPROVED USE DISCLOSURE
The University of Cincinnati and i3 Health require CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc. and Sanofi Genzyme.